ResMed Inc. filed an 8-K on November 19, 2026, disclosing the retirement of director Ronald Taylor, the approval of a redesigned fiscal year 2027 performance-based restricted stock unit program for named executive officers, and the results of stockholder votes taken at its November 18, 2026 annual meeting.

Key Highlights

  • Board reduced to ten: Ronald Taylor did not seek re-election; his term expired at the conclusion of the November 18, 2026 annual meeting, reducing the board from eleven to ten directors.
  • New PSU design approved: The Compensation and Leadership Development Committee approved a new PSU award form on November 19, 2026, shifting from an absolute and relative TSR vesting structure to one based on Adjusted EPS and Adjusted Revenue goals measured over three annual periods.
  • TSR modifier range: A relative TSR modifier of 0.75 to 1.25 applies, based on the company's TSR percentile rank versus the S&P 500 Index, with a 200% maximum cap on total earned PSUs.
  • Payout range per metric: Performance at threshold, target, and maximum results in payouts of 50%, 100%, and 200%, respectively, of target PSUs allocated to that metric.
  • Ten directors elected: All ten nominees were elected at the annual meeting, each to serve until the 2027 annual meeting.
  • Auditor ratified: Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending June 30, 2027, with 109,994,316 votes in favor.
  • Say-on-pay approved: Advisory compensation approval received 95,067,879 votes in favor and 12,883,333 against, with 4,859,690 broker non-votes.

ResMed Overhauls Executive PSU Structure for Fiscal Year 2027

According to the filing, the Compensation and Leadership Development Committee (CLDC) of ResMed's board approved a new form of Performance-Based Restricted Stock Unit Award Agreement on November 19, 2026, under the ResMed Inc. 2009 Incentive Award Plan. The filing states that the new design "reflects a change from the PSU design used in recent years, under which PSU awards vested based on the Company's absolute total stockholder return ('TSR') and relative TSR, respectively." Under the new structure, performance is measured over three consecutive fiscal years beginning with fiscal year 2027, against annual Adjusted EPS and Adjusted Revenue goals set by the CLDC for each year. NYSE:RMD is the exchange and ticker for ResMed's common stock, $0.004 par value.

The filing explains that one-third of the target PSUs is allocated to each annual measurement period and split equally between the two metrics. Following the end of the full performance period, payout percentages for each metric are averaged across the three years and weighted equally. That resulting percentage is then multiplied by a relative TSR modifier, which ranges from 0.75 at or below the 25th percentile to 1.25 at or above the 75th percentile of the S&P 500 Index, with 0.95 at the 50th percentile and 1.00 at the 60th percentile. The filing specifies that "in no event may more than 200% of the target PSUs be earned."

The filing also details vesting provisions for various termination scenarios. PSUs vest at 100% of target upon death or disability. Upon a qualifying retirement (defined as attaining age 60 with at least five years of continuous service, other than a termination for cause), or a termination without cause or resignation for good reason on or after the second anniversary of the grant date, executives remain eligible for a prorated portion based on actual performance. The PSUs include "double-trigger" vesting provisions in connection with a change in control, as described in the filing.

What Was Disclosed

ResMed's 8-K covers three items: the retirement of director Ronald Taylor and the board's reduction to ten members, the CLDC's approval of a redesigned FY2027 PSU program tied to financial metrics and a TSR modifier, and stockholder vote results from the November 18, 2026 annual meeting including director elections, auditor ratification, and an advisory say-on-pay vote.